75473-11-9

Usage

Uses

As of now, no specific information on the uses or applications of 1-(2-Methyl-3-nitrophenyl)ethanone is readily available, suggesting that it might be primarily used or studied in the realm of basic chemistry or chemical research. However, given its chemical structure, it could potentially be used in various industries once its properties and reactivity are better understood. Possible applications could include:
Used in Chemical Research:
1-(2-Methyl-3-nitrophenyl)ethanone is used as a research compound for studying its chemical properties and reactivity patterns, which could lead to the development of new chemical processes or products.
Used in Pharmaceutical Industry:
Once its properties are better understood, 1-(2-Methyl-3-nitrophenyl)ethanone could potentially be used as an intermediate in the synthesis of pharmaceutical compounds, given its complex molecular structure.
Used in Material Science:
1-(2-Methyl-3-nitrophenyl)ethanone's unique structure may also make it a candidate for use in the development of new materials with specific properties, such as in the fields of polymer chemistry or materials engineering.

InChI:InChI=1/C9H9NO3/c1-6-8(7(2)11)4-3-5-9(6)10(12)13/h3-5H,1-2H3

Upstream product

• 120100-32-5 diethyl 2-(2-methyl-3-nitrobenzoyl)malonate 
• 136774-69-1 ethyl 3-(2-methyl-3-nitrophenyl)-3-oxopropionate 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 39053-41-3 2-methyl-3-nitrobenzoyl chloride 

Downstream Products

• 209795-96-0 1-(2-methyl-3-aminophenyl)ethanone 
• 75473-40-4 N-{[3-(2-Methyl-3-nitro-benzoyl)-thiophen-2-ylcarbamoyl]-methyl}-isobutyramide 
• 75473-55-1 1-Methyl-5-(2-methyl-3-nitro-phenyl)-7-nitro-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-47-1 5-(2-Methyl-3-nitro-phenyl)-7-nitro-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-54-0 7-Chloro-1-methyl-5-(2-methyl-3-nitro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-28-8 2-Amino-N-[3-(2-methyl-3-nitro-benzoyl)-thiophen-2-yl]-acetamide 
• 75473-24-4 2-Iodo-N-[3-(2-methyl-3-nitro-benzoyl)-thiophen-2-yl]-acetamide 
• 75473-19-7 2-Chloro-N-[3-(2-methyl-3-nitro-benzoyl)-thiophen-2-yl]-acetamide 
• 75473-46-0 7-Chloro-5-(2-methyl-3-nitro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-51-7 1-Methyl-5-(2-methyl-3-nitro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-34-6 5-(2-Methyl-3-nitro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-43-7 7-Chloro-5-(2-methoxy-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-50-6 5-(2-Methoxy-phenyl)-1-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 75473-32-4 5-(2-Methoxy-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 

Relevant academic research and scientific papers

4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders.

SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF

The present invention relates to substituted Pyridyl-cycloalkyl- carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.

BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS

β-Substituted γ-amino acids, β-substituted γ-amino acid derivatives, and β-substituted γ-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates, capable of passing through the blood-brain barrier, and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres and methods of using the compounds for treating tumors are also disclosed. The β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres exhibit an improved selectivity toward tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted γ-amino acid derivatives and β-substituted γ-amino acid analogs and (bio)isosteres exhibit an increased efficacy on a variety of tumor types.

Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence

A compound of formula I or of tautomeric formula II wherein: R1 and R5 are each independently H, F, Cl, Br, CH2F, CHF2, CF3, Me, or OMe; R2 and R4 are each independently H, a branched C3-6-alkyl, F, Cl, Br, CH2F, CHF2, CF3 or Me, wherein at least one of the groups R2 or R4 is a branched C3-6-alkyl; and R3 is H, F, Cl, Br, CH2F, CHF2, CF3 or Me, or a pharmacologically acceptable salt thereof, pharmaceutical compositions containing these compounds, and their use in treating urinary incontinence or a bladder disease.

NOVEL FENAMIC ACID METHYL HYDROXAMATE DERIVATIVES HAVING CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITION

The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods

Process for preparing highly pure 1-nitroanthraquinone

1-Nitroanthraquinone is produced in highly pure form by a process comprising the steps of partially oxidizing 3-nitro-o-xylene (I) to 2-methyl-3-nitrobenzoic acid (II) converting II to 2-methyl-3-nitrobenzoyl halide (III), converting III to the novel intermediate 2-methyl-3-nitrobenzophenone (IV), oxidizing IV to 2-benzoyl-6-nitrobenzoic acid (V) and cyclizing V to 1-nitroanthraquinone.